Combined treatment for recurrent prostate cancer after radical prostatectomy results in decreased long-term all-cause and cancer-specific mortality.
During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively.
No increased risk of dementia for androgen deprivation therapy use versus nonuse.
Patient motivation is pivotal to the success of exercise interventions, researchers noted.
The risk of dementia was 2-fold higher among ADT users.
Study tested the combination in men with treatment-naïve prostate cancer and bone metastasis.
Ongoing use of androgen-deprivation therapy (ADT) for up to 36 months is not associated with cognitive decline among men with prostate cancer.
Men with 1 or 2 copies of the HSD3B1 (1245C) allele are more likely to experience disease progression.
Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.
Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.
Superior median, 5-year OS for prostate RT plus ADT versus ADT alone in propensity score analyses.
Radiation therapy also is associated with a greater likelihood of fractures.
Adding short-term androgen suppression to salvage radiotherapy may benefit men with prostate cancer who have undergone radical prostatectomy.
New findings show metabolic changes suggesting that a carbohydrate-restricted diet may improve insulin sensitivity.
Researchers find 23% increased risk compared to men who received other treatments.
Adding bevacizumab to androgen deprivation therapy (ADT) resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer.
The advice is useful as clinicians wait for formal guidelines.
Combined radiotherapy remains controversial due to the increased potential for toxicities.
Anti-androgen therapy during and after salvage radiotherapy in patients with localized prostate cancer significantly improved long-term overall survival.
The finding of lower bladder cancer incidence in patients receiving pelvic radiation contrasts with previous research.
In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.
A 12-gene androgen deprivation therapy resistance signature may help guide therapeutic decision making after radical prostatectomy.
Higher risks of several clinically relevant adverse effects compared with surgical castration.
The study found no association with obesity, however, unlike previous studies.
A new study by University of Pennsylvania and Stanford researchers highlights a possible link between men who receive androgen deprivation therapy (ADT) and the future onset of Alzheimer's disease.
The risk is highest among patients who switch from anti-androgen to GnRH agonist therapy.
The time to PSA progression in men with relapsing or locally advanced PCa was similar with intermittent and continuous androgen deprivation.
Compared with combination treatment, radiation therapy alone was linked with 64% and 83% lower odds of early death and death from cardiac causes among patients with co-existing illnesses.
This approach is, or should be, the standard of care for locally advanced PCa, some researchers say.
Additional novel medical therapies to treat prostate cancer and earlier use of the existing medical therapies are the future of prostate cancer management.
Renal and Urology News Articles
- Novel Calcimimetic Approved for Secondary Hyperparathyroidism
- Prostate Cancer Treatment Prolongs Survival
- Misplaced Mobile Devices Lead to HHS Investigations, Millions in Fines
- PCa Salvage Radiation Plus Anti-Androgen Therapy Improves Outcomes
- Targeted Biopsy Improves Detection of Significant PCa in Black Men
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)